Clinical data on restless legs syndrome: a dose-finding study with cabergoline.
Current treatment options for restless legs syndrome (RLS), based on the American Academy of Sleep Medicine practice parameters, favor dopaminergic agents. The drug of first choice is levodopa, which is now licensed for RLS in two European countries. However, the short duration of action and augmentation of symptoms under therapy may limit the clinical use of levodopa, especially in severely affected patients. An open pilot study shows that the long-acting dopamine agonist cabergoline is a promising new tool in the treatment of RLS. Results of a double-blind, controlled trial are pending.
Stiasny
K
K
Department of Neurology, Center of Nervous Diseases, Marburg, Germany. Stiasny@mailer.uni-marburg.de
D000328:Adult; D000368:Aged; D000077465:Cabergoline; D015259:Dopamine Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004873:Ergolines / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D012148:Restless Legs Syndrome / Q000188:drug therapy*; D011795:Surveys and Questionnaires
D015259:Dopamine Agents; D004873:Ergolines; D000077465:Cabergoline